Skip to main content
. 2011 Dec 13;93(4):674–681. doi: 10.1093/cvr/cvr330

Figure 4.

Figure 4

(A) Clopidogrel competes with CYP3A luminogenic substrate for metabolism in RASMC. Data represent fold change (n = 3 triplicate samples) from vehicle ±SE. (B) PXR activation in the rat aorta by PCN (10 μmol/L 24 h) enhances the anti-platelet aggregation effects of clopidogrel. Ten microlitres of conditioned media, from ex vivo cultured rat aorta incubated with clopidogrel (100 μmol/L 1 h post-PCN), were incubated with PRP for 30 min prior to 1 μmol/L ADP stimulation. Data represent aggregation/mg aortic protein as a percentage of control ±SE, n = 4, duplicate samples; *P < 0.05 vs. vehicle control determined by one-sample t-test.